In autoimmune diseases, SIRT6 inhibitors effectively delay the onset of experimental autoimmune encephalomyelitis (EAE) via the following mechanism: inhibition of SIRT6 reduces the expression of CD40 on lymph node DCs, decreases encephalitogenic T cell infiltration, and decreases the ability of CXCR4+ DCs to migrate into the lymph nodes of EAE mice. Here, SIRT6 is linked to experimental autoimmune encephalomyelitis.